This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gao, B. Articles by Minna, J. D. Search for Related Content PubMed PubMed Citation Articles by Gao, B. Articles by Minna, J. D.

RASSF1A Polymorphism A133S Is Associated with Early Onset Breast Cancer in BRCA1/2 Mutation Carriers

¹ Hamon Center for Therapeutic Oncology Research, ² Simmons Comprehensive Cancer Center, ³ Department of Pharmacology, ⁴ Division of Biostatistics, Departments of ⁵ Pediatrics and ⁶ Surgery, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas; ⁷ Department of Medicine, The University of Chicago Medical Center, Chicago, Illinois; ⁸ Department of Oncology, Center for Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts; and ⁹ Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, Texas

Requests for reprints: Boning Gao, Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Boulevard, Dallas, TX 75390-8593. Phone: 214-648-4915; Fax: 214-648-4940; E-mail: boning.gao{at}utsouthwestern.edu.

The tumor suppressor gene RASSF1A regulates cell cycle progression, apoptosis, and microtubule stability and is inactivated by promoter methylation in 50% of breast cancers. It has been shown previously that the polymorphism A133S in RASSF1A reduces its ability to regulate cell cycle progression and this polymorphism is associated with an increased risk of breast cancer. We analyzed the frequency of RASSF1A A133S in 190 Caucasian women without breast cancer and 653 patients with breast cancer including 138 BRCA1 and BRCA2 (BRCA1/2) mutation carriers, 395 non–BRCA1/2 mutations carriers, and 120 untested for BRCA1/2 mutations. Patients with breast cancer had a higher frequency of A133S than the controls [P = 0.017; odds ratios (OR), 1.71; 95% confidence intervals (95% CI), 1.10–2.66]. There is also a higher frequency of A133S in patients with higher familial breast cancer risk (P = 0.029; OR, 1.76; 95% CI, 1.06–2.92) and patients carrying BRCA1/2 mutations (P = 0.037, OR, 1.82; 95% CI, 1.04–3.18). Importantly, we found that the co-occurrence of a BRCA1 or BRCA2 mutation and A133S in RASSF1A was associated with earlier onset of breast cancer compared with those individuals with either a BRCA1/2 mutation or the A133S polymorphism alone (36.0 versus 42.0 years old, P = 0.002). Our data suggest that the presence of the RASSF1A A133S polymorphism is associated with breast cancer pathogenesis in general and modifies breast cancer age of onset in BRCA1/2 mutations carriers. Our results warrant a large-scale study to examine the effect of the A133S polymorphism in the development of breast and other types of cancers. [Cancer Res 2008;68(1):22–5]

This article has been cited by other articles:

				G. Davey Smith Smoking and lung cancer: causality, Cornfield and an early observational meta-analysis Int. J. Epidemiol., October 1, 2009; 38(5): 1169 - 1171. [Full Text] [PDF]